GT-929

Single-drug dose escalation phase: Primary purpose: To evaluate the safety and tolerability of GT929 for the treatment of relapsed or refractory non-Hodgkin lymphoma (rrNHL) or relapsed or refractory multiple myeloma (rrMM); To explore dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) or recommended dose (RP2D) for Phase II studies; Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of GT929 in patients with rrNHL or rrMM; To evaluate the preliminary efficacy of GT929 in rrNHL or rrMM. Dose expansion phase: Primary purpose: To evaluate the efficacy of GT929 in rrNHL or rrMM; Secondary purpose: To evaluate the safety of GT929 in rrNHL or rrMM.